Biomira Diagnostic's (Canada) Truquant test on fast track in US
This article was originally published in Clinica
Biomira Diagnostics' (Canada) PMA for the Truquant BR blood test kit for detecting recurrent breast cancer, which has been given expedited review status in the US, will be reviewed by an FDA advisory committee this month. The Immunology Devices Advisory Panel will consider the application on September 21st. Biomira's Truquant test kits for breast, ovarian and colorectal cancer are already marketed in Canada, Europe and Japan.